Vor Bio announces a $55.6 million PIPE to fund clinical trials and expects to report updated data in 2025. Vor Bio, a clinical-stage cell and genome engineering company, announced a securities ...
Thursday, Vor Biopharma Inc. (NASDAQ:VOR) announced new clinical data from its ongoing Phase 1/2 VBP101 study of patients with relapsed/refractory acute myeloid leukemia (AML) receiving trem-cel ...
VOR (Very High Frequency Omni-Directional Range) stations are traditional ground-based radio navigation aids that have guided aircraft since the 1930s by broadcasting signals allowing aircraft to ...
Vor Biopharma Inc. (VOR) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting ...
Vor Biopharma, Inc. is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. It is focused on rapidly advancing telitacicept, a novel dual-target fusion protein, ...
Vor Biopharma Inc. (VOR) stock jumped to a high of $12 yesterday, gaining >20%, but as I discovered to my detriment recently, all is not exactly what it seems at the company. In this post I revisit a ...
Even legally compliant VORs (within 14 CFR 91.171 limits) can have errors that result in significant lateral displacement, potentially compromising obstacle clearance, especially far from the VOR ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results